Daliresp (DA-li-resp), a new oral tablet for severe COPD in patients with chronic bronchitis

July 2011

You'll hear about Daliresp (DA-li-resp), a new oral tablet for severe COPD in patients with chronic bronchitis.

Daliresp (roflumilast) is the first in a new class of oral phosphodiesterase 4 inhibitors. It works by reducing lung inflammation.

It's added to the usual bronchodilator therapy to decrease exacerbations...but only for severe, chronic COPD.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote